Stock GLMD GALMED PHARMACEUTICALS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company Galmed Pharmaceuticals Ltd.

Equities

GLMD

IL0011313900

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 10:22:34 2024-07-09 am EDT 		5-day change 1st Jan Change
0.296 USD +1.79% Intraday chart for Galmed Pharmaceuticals Ltd. +4.03% -34.77%
May. 30 Galmed Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 04 Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).

Number of employees: 6

Managers

Managers TitleAgeSince
Allen Baharaff CEO
 Chief Executive Officer 59 99-12-31
Doron Cohen DFI
 Director of Finance/CFO 57 22-01-31
Guy Nehemya COO
 Chief Operating Officer 39 13-09-30
Liat Hayardeny CTO
 Chief Tech/Sci/R&D Officer 57 16-09-06
Yohai Stenzler AUD
 Comptroller/Controller/Auditor 41 14-05-31

Members of the board

Members of the board TitleAgeSince
David Sidransky BRD
 Director/Board Member 64 14-05-31
Carol Brosgart BRD
 Director/Board Member 72 17-06-06
Allen Baharaff CEO
 Chief Executive Officer 59 99-12-31
Shmuel Nir BRD
 Director/Board Member 62 06-12-31
Amir Poshinski BRD
 Director/Board Member 63 20-06-15

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 6,358,747 6,126,245 ( 96.34 %) 0 96.34 %

Shareholders

NameEquities%Valuation
Allen Baharaff
3.790 %
227,790 3.790 % 62 642 $
CVI Holdings LLC
1.242 %
74,665 1.242 % 20 533 $
Walleye Capital LLC
0.6991 %
42,012 0.6991 % 11 553 $
Two Sigma Advisers LP
0.3705 %
22,267 0.3705 % 6 123 $
Two Sigma Securities LLC
0.2713 %
16,306 0.2713 % 4 484 $
Morgan Stanley Capital Services LLC
0.2412 %
14,498 0.2412 % 3 987 $
Shmuel Nir
0.0543 %
3,262 0.0543 % 897 $
UBS Securities LLC
0.0376 %
2,260 0.0376 % 622 $
David Sidransky
0.008320 %
500 0.008320 % 138 $
Guy Nehemya
0.006240 %
375 0.006240 % 103 $

Company contact information

Galmed Pharmaceuticals Ltd.

16 Abba Hillel Road

5250608, Ramat Gan

+972 3 693 8448

http://galmedpharma.com
address Galmed Pharmaceuticals Ltd.(GLMD)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.2908 USD
Average target price
1 USD
Spread / Average Target
+243.88%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
GALMED PHARMACEUTICALS LTD. Stock Galmed Pharmaceuticals Ltd.
-34.77% 1.85M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+18.63% 124B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+18.56% 114B
ARGENX SE Stock argenx SE
+20.79% 25.83B
BIONTECH SE Stock BioNTech SE
-23.84% 19.42B
GENMAB A/S Stock Genmab A/S
-18.19% 16.2B
BEIGENE, LTD. Stock BeiGene, Ltd.
-19.93% 15.31B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+56.97% 14.32B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.01% 14.31B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-49.33% 14.19B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. GLMD Stock
  4. Company Galmed Pharmaceuticals Ltd.